The ongoing trial NCT05572684 using NC410 (the dimeric LAIR-2 protein fused to a human IgG1 Fc domain, see Chapter 4.1) in combination with the anti-PD1 pembrolizumab in MSS and low-microsatellite stable CRC or ovarian cancer may give some insights into the cooperation of conventional ICI and LAIR1 [227]. Here, RPL17 is linked to ovarian carcinoma.